MedTrace Logo

Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry

NCT02896218 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-05-29

No results posted yet for this study

Summary

Vancomycin is a glycopeptide antibiotic that is the first line antibiotics for the treatment of serious gram-positive infections involving methicillin-resistant Staphylococcus aureus (MRSA). Its therapeutic window is narrow, so there is a need to monitor serum vancomycin concentration in clinical practice, especially in the critically ill patients. So far, few studies have investigated the clinical outcomes of the dosage strategy that vancomycin dosage is administered and adjusted individually using PPK and Bayesian methods based on observed concentrations. The objective of this study is to investigate the effectiveness, safety and economics of the vancomycin individualized dosing service provided by pharmacists.

Conditions

  • Critically Ill

Interventions

OTHER

Pharmacists consultation

Pharmacists consultation of vancomycin individualized dosing strategy

Sponsors & Collaborators

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Qinggang Ge, M.D. · Peking University Third Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02896218 on ClinicalTrials.gov